Human CA 72-4 ELISA kit is intended for measuring in vitro quantitative concentrations of cancer antigen 72-4 (CA 72-4, tumor associated antigen 72, CA72-4, TAG-72) in human serum or plasma samples. This assay has a minimum sensitivity limit of 0.79 U/ml.
Please note that small volumes of the CA 72-4 elisa kit can sometimes get entrapped in the seal of the vial when it is shipped and stored. If this happens, you will need to centrifuge the vial on a hard surface to dislodge any liquid.
Cancer antigen 72-4 (CA72-4) was originally discovered as an antigenic determinant that is recognised by B 72.3 and it was named as TAG-72 (tumor associated antigen 72). TAG-72 protein has a molecular weight of 48 kDa.
Elevated concentrations of tumor biomarker CA 72-4 using either samples of plasma or serum for analysis purpose have been identified in a large number of malignant diseases, examples include cancer of the stomach, pancreas, ovaries, cervix, colon and endometrium. However, these are found to be rarely expressed in normal or benign adult tissues. CA 72-4 is of particular interest for many clinical healthcare hospital departments, since it displays excellent specificity and has the capability in diagnosing and monitoring many different types of neoplastic diseases. Tumor markers are substances that are produced by the host by abnormal secretions of malignant cells.
CLINICAL EFFICACY AND PERFORMANCE OF CA 72-3
CA 72 serum marker is seen as a great new tool for diagnostics, particularly in relation to the management of carcinoma patients. There are also many new studies that evidence the clinical usefulness of CA 72-4 when examining gastric , gastrointestinal , colorectal and ovarian cancer.
Medical diagnosis and healthcare management for both male and female related diseases can lead to a high quality therapeutic treatment being offered to individuals.
There have also been several studies which have focused on the potential clinical usefulness of CA 72-4 in gynaecological and gastrointestinal (GI) cancer, these have shown a sensitivity of approx. 50% in ovarian cancer and 40% in gastric and colorectal cancer, however, the overall specificity was greater than 95%. There is also a good correlation between the levels of CA 72-4 and tumor size and stage. Gastrointestinal malignant diseases has been found to demonstrate a significant elevations in the cancer antigen 72-4 serum levels that could be predictive of recurrent disease. CA 72-4 is now regarded as the primary marker of choice for therapeutic monitoring and the subsequent follow up care of gastrointestinal patients.
Furthermore, studies suggest that CA 72-4 has usefulness when confirming the benign nature of ovarian endometriomas in females presenting with high levels of CA 125.
Clinical based laboratories that have accreditation certificates and work toward conformity assessment models will help in improving the identification of tumor antigens, many cancer biomarkers are also able to travel (metastasize) to different parts of the human body. The use of combination therapy when two or more biological markers are used together has been found to improve the treatment, survival rate and the specific detection process.
In many cases this has led to an increased sensitivity being achieved without making any substantial change to the overall specificity, this has led to improving the possibility of monitoring these patients. In order to properly manage metastatic and recurring cancers, it is fundamental to assess the actual response following the anti tumour therapy process.
CA 72-4 is one of the best markers on the market when it comes to therapeutic monitoring and planning follow up care for patients with gastrointestinal cancer. It has also been used as an appropriate marker in therapeutic monitoring and care planning for patients.
Cancer antigen 72-4 can also be positively associated with h. pylori infection status, gastric ulcers, polyps and gastritis. H pylori is a pathogenic bacteria.
CA 72-4 can be used for both diagnostic applications and research use since the kit is CE and IVD marked. Please note that the sensitivity and range can be subject to change, and if you have any queries you should contact us and check the user guide / data sheet. For the best and most accurate findings, the sample concentrations should be diluted to mid range of the kit.
CA 72-4 ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Microtiterwells: Coated with anti-CA 72-4 antibody (monoclonal).
- Standard (0-4): Concentrations 0, 3, 20, 50, 100 U/mL.
- Control Low & High (Lyophilized).
- Sample Diluent.
- Enzyme Conjugate (10x Conc.): Anti-CA 72-4 antibody conjugated to horseradish peroxidase.
- Conjugate Diluent.
- Substrate Solution: Tetramethylbenzidine (TMB).
- Stop Solution: Contains 1 N acidic solution.
- Wash Solution (40x Concentrated).
The minimum detection sensitivity level of human cancer antigen 72-4 (CA 72-4, TAG-72, tumor associated antigen 72, CA72-4) using current human CA 72-4 ELISA kit was 0.79 U/ml. The dynamic range for this assay is 3.0 – 100.0 U/ml.
– Cancer Antigen 72-4 (CA 72-4): ELISA
– Assay Dynamic Range: 0.78 – 100 U/mL
– Specificity of Antibodies (Cross Reactivity): None
– Analytical Sensitivity: 0.79 U/mL
– Intra Assay: 1.6 – 2.4%
– Inter Assay: 4.2 – 4.8%
– Recovery: 88.2 – 106.8%
– Linearity: 86.3 – 112.3%
– Interfering Substances: Haemoglobin (up to 4 mg/mL), Bilirubin (up to 0.5 mg/mL) and Triglyceride (up to 7.5 mg/mL) have no influence on the assay results. Triglycerides > 7.5 mg/mL will -result in decreased values.
– Drug Interference: None
– High-Dose-Hook Effect: No hook effect was observed up to 6,400 U/mL of CA 72-4.
- CA 72-4 serum marker–a new tool in the management of carcinoma patients. Cancer Invest. (1995) 13 (2): 227-38. Review. Guadagni F., et al.
- Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. (2004) 58 (1): 24-38. Review. Gadducci A., et al.
- The use of monoclonal antibody B72.3 in the management of gynecologic malignancies. Yale J Biol Med. (1988) 61 (4): 351-66. Review. Simpson J. and Schlom J.
- “Epidemiology of endometriosis,” Obstetrics and Gynecology Clinics of North America, (1997) vol. 24, no. 2, pp. 235-258. B. Eskenazi and M. L. Warner. View at: Publisher Site | Google Scholar
- Endometriosis. The New England Journal of Medicine. (2010) vol. 362, no. 25, pp. 2389-2398. L. C. Giudice. View at: Publisher Site | Google Scholar
- The European Society of Human Reproduction and Embryology guideline for the diagnosis and treatment of endometriosis: an electronic guideline implementability appraisal. Implementation Science. (2011) vol. 6, no. 1, article 7,. L. J. E. W. van Dijk, W. L. D. M. Nelen, T. M. D’Hooghe et al.
- A comparison of the cyclic variation in serum levels of CA125 across the menstrual cycle using two commercial assays. Biological Research For Nursing. (2012) vol. 14, no. 3, pp. 250-256. M. R. McLemore, B. E. Aouizerat, K. A. Lee et al.
- A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA. (1981), 78, 3199-3203. Colcher, D.; Hand, P.H.; Nuti, M.; Schlom, J.
- Diagnostic Value of Serum Insulin Like Growth Factor Binding Protein 7 in Colorectal Cancer. (2020) B Qui, L Chu, X Li, Y Peng.
- Demonstration of tumor-specific antigens in human colonic carcinomata by Immunology tolerance and absorption techniques. J Exp Med (1965) 121: 439-462. gold P, Freedman SO.
- Full Name: Cancer Antigen 72-4 (CA 72-4) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 0.79 U/ml